NCT07518784 Accurate Point of Care Liver Disease Diagnostics (Phase 2)
| NCT ID | NCT07518784 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Diego |
| Condition | MASLD |
| Study Type | OBSERVATIONAL |
| Enrollment | 26 participants |
| Start Date | 2026-04-08 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 26 participants in total. It began in 2026-04-08 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver (LiverScope®). We will compare LiverScope® to other methods to evaluate the liver, including advanced conventional liver MR exams. MR exams are common exams used to monitor MASLD (also known as NAFLD). Conventional MR scanners use magnetic fields and radio waves to make pictures of the liver. LiverScope® is a small, portable MR-based device that uses similar, but simplified technology, and can be used on top of an exam table in an outpatient setting. LiverScope® currently is not approved for clinical use. In this second phase of the study, we took what we learned in the first phase to optimize the LiverScope® device and are now testing to see how LiverScope® measurements compare to MR after these optimizations. Study participants will be asked to complete a one-time visit which includes: * LiverScope exam * MR exam * FibroScan exam (optional) * Blood draw * Completion of study questionnaires
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Known or clinically suspected MASLD * BMI greater than 27 kg/m\^2 and less than 45 kg/m\^2 at the time of referral * Ability to lie on LiverScope® device table for about 60 minutes * Ability to hold breath repeatedly for about 20 seconds during MR and LiverScope® exams * Willing and able to undergo all study procedures Exclusion Criteria: * UCSD study personnel or Livivos study personne * Contraindications to MR * Potential participant states that she knows that she is pregnant, thinks she may be pregnant, or states that she is trying to become pregnant. * Known chronic liver disease other than MASLD
Contact & Investigator
Claude B Sirlin, MD
PRINCIPAL INVESTIGATOR
University of California, San Diego
Frequently Asked Questions
Who can join the NCT07518784 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying MASLD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07518784 currently recruiting?
Yes, NCT07518784 is actively recruiting participants. Contact the research team at ycovarrubias@health.ucsd.edu for enrollment information.
Where is the NCT07518784 trial being conducted?
This trial is being conducted at La Jolla, United States.
Who is sponsoring the NCT07518784 clinical trial?
NCT07518784 is sponsored by University of California, San Diego. The principal investigator is Claude B Sirlin, MD at University of California, San Diego. The trial plans to enroll 26 participants.